FR2228488B1 - - Google Patents

Info

Publication number
FR2228488B1
FR2228488B1 FR7415703A FR7415703A FR2228488B1 FR 2228488 B1 FR2228488 B1 FR 2228488B1 FR 7415703 A FR7415703 A FR 7415703A FR 7415703 A FR7415703 A FR 7415703A FR 2228488 B1 FR2228488 B1 FR 2228488B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7415703A
Other versions
FR2228488A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH672273A external-priority patent/CH578534A5/de
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of FR2228488A1 publication Critical patent/FR2228488A1/fr
Application granted granted Critical
Publication of FR2228488B1 publication Critical patent/FR2228488B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
FR7415703A 1973-05-11 1974-05-07 Expired FR2228488B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH672273A CH578534A5 (en) 1973-05-11 1973-05-11 Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH393574 1974-03-21

Publications (2)

Publication Number Publication Date
FR2228488A1 FR2228488A1 (fr) 1974-12-06
FR2228488B1 true FR2228488B1 (fr) 1977-05-06

Family

ID=25694221

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7415703A Expired FR2228488B1 (fr) 1973-05-11 1974-05-07

Country Status (9)

Country Link
US (1) US3960868A (fr)
JP (1) JPS5018480A (fr)
AT (1) AT332406B (fr)
AU (1) AU6877174A (fr)
CA (1) CA1034124A (fr)
DE (1) DE2421121A1 (fr)
FR (1) FR2228488B1 (fr)
GB (1) GB1467061A (fr)
NL (1) NL7405910A (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190659A (en) 1973-08-27 1980-02-26 Sandoz, Inc. Pharmaceutical preparation and use of 4-hydroxy-2-quinolinone-3-carboxylic acid esters
US4187309A (en) * 1977-06-20 1980-02-05 Sandoz, Inc. 4-Hydroxy-2-quinolinone-3-carboxylic acids and salts thereof
US4273930A (en) * 1977-06-20 1981-06-16 Sandoz, Inc. 4-Hydroxy-2-quinolinone-3-carboxylic acid esters
US4281131A (en) * 1977-06-20 1981-07-28 Sandoz, Inc. 4-Hydroxy-2-quinolinone-3-carboxylic acids and salts thereof
US4128649A (en) * 1977-06-29 1978-12-05 Sandoz, Inc. 4-Hydroxy-pyrido[2,3-b]pyridine-2(1H)-one-3-carboxylic acids and esters
US4119720A (en) * 1977-07-06 1978-10-10 Sandoz, Inc. Unsaturated esters of 4-hydroxy-2-quinolinone-3-carboxylic acids and salts thereof
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US4169893A (en) * 1978-03-13 1979-10-02 Sandoz, Inc. 4-hydroxy-naphthpyridine-2(1h)-one-3-carboxylic acids and esters
FR2482596A1 (fr) * 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4463058A (en) * 1981-06-16 1984-07-31 Atlantic Richfield Company Silicon carbide whisker composites
FR2509728A1 (fr) * 1981-07-17 1983-01-21 Roussel Uclaf Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
JPS58105965A (ja) * 1981-12-15 1983-06-24 Nippon Shinyaku Co Ltd 置換キノリンカルボン酸誘導体
JPS58219166A (ja) * 1982-06-14 1983-12-20 Nippon Shinyaku Co Ltd ４−キノロン誘導体
DE3430800A1 (de) * 1984-08-22 1986-03-06 Bayer Ag, 5090 Leverkusen Anzinpigmente
EP0184384B1 (fr) * 1984-12-06 1989-08-02 Pfizer Inc. Acides dihydroquinolonecarboxyliques substitués et compositions antibactériennes les contenant
US4929613A (en) * 1987-08-26 1990-05-29 Warner-Lambert Company Antibacterial agents
DE3811341A1 (de) * 1987-10-09 1989-04-27 Bayer Ag In 7-stellung c-verknuepfte chinolon- und 1,8-naphthyridin-4-on-carbonsaeure und ein verfahren zu ihrer herstellung
US5103040A (en) * 1988-06-21 1992-04-07 Pfizer Inc. 6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives and intermediates therefor
US5104868A (en) * 1988-06-21 1992-04-14 Pfizer Inc. Tricyclic derivatives of 7-substituted-6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acids and esters
US5039682A (en) * 1988-06-21 1991-08-13 Pfizer Inc. 6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives and intermediates therefor
US5233091A (en) * 1988-06-21 1993-08-03 Pfizer Inc. 6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acid derivatives and intermediates therefor
CA2053926A1 (fr) * 1989-04-28 1990-10-29 Genkichi Ohta Agent anti-vih
US5310913A (en) * 1989-06-09 1994-05-10 Kabi Pharmacia Aktiebolag Derivatives of quinoline-3-carboxanilide
US4992449A (en) * 1990-02-01 1991-02-12 American Cyanamid Company 7-(substituted)cycloalkylamino-1-(substituted)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids
JPH07110853B2 (ja) * 1990-09-07 1995-11-29 シェリング・コーポレーション 抗ウイルス化合物および抗高血圧化合物
AU8448491A (en) * 1990-09-07 1992-03-30 Schering Corporation Antiviral compounds and antihypertensive compounds
US5179093A (en) * 1991-05-10 1993-01-12 Schering Corporation Quinoline-diones
DE4138820A1 (de) * 1991-11-26 1993-05-27 Basf Ag Chinolin-3-carbonsaeureamide, deren herstellung und verwendung
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
CA2309882A1 (fr) * 1997-12-22 1999-07-01 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides et hydrazides utilises comme agents antiviraux
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
JP2009544732A (ja) * 2006-07-26 2009-12-17 ノバルティス アクチエンゲゼルシャフト ウンデカプレニルピロホスフェートシンターゼの阻害剤
CA2813711A1 (fr) 2010-10-14 2012-04-19 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoleine-3-carboxanilides en tant qu'activateurs d'ahr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB830832A (en) * 1957-02-15 1960-03-23 Ici Ltd New quinolones and therapeutic compositions containing them
US3452026A (en) * 1966-03-15 1969-06-24 Bristol Myers Co Substituted 1,2,3,4-tetrahydroquinolines
US3542851A (en) * 1966-07-01 1970-11-24 Merck & Co Inc Novel acrylate,amines and ethers
US3761592A (en) * 1969-03-18 1973-09-25 R Mizzoni Quinoline derivatives exhibiting growth promoting and anticoccidial effects
US3506667A (en) * 1969-05-01 1970-04-14 Warner Lambert Pharmaceutical Furo quinoline carboxylates
BE759357A (fr) * 1969-11-24 1971-04-30 Sumitomo Chemical Co Derives de 4-thioxoquinoleine
DE2103805C3 (de) * 1970-01-28 1980-03-20 Sumitomo Chemical Co., Ltd., Osaka (Japan) Verfahren zur Herstellung von N-substituierten 6,7-Methylendioxy-4chinolonen

Also Published As

Publication number Publication date
AU6877174A (en) 1975-11-13
NL7405910A (fr) 1974-11-13
FR2228488A1 (fr) 1974-12-06
US3960868A (en) 1976-06-01
JPS5018480A (fr) 1975-02-26
DE2421121A1 (de) 1975-01-16
ATA387574A (de) 1976-01-15
GB1467061A (en) 1977-03-16
AT332406B (de) 1976-09-27
CA1034124A (fr) 1978-07-04

Similar Documents

Publication Publication Date Title
AR201758A1 (fr)
AU476761B2 (fr)
AU465372B2 (fr)
FR2228488B1 (fr)
AR201235Q (fr)
AU474593B2 (fr)
AU474511B2 (fr)
AU474838B2 (fr)
AU465453B2 (fr)
AU465434B2 (fr)
AU471343B2 (fr)
AU450229B2 (fr)
AU476714B2 (fr)
AU472848B2 (fr)
AU466283B2 (fr)
AU476696B2 (fr)
AU477823B2 (fr)
AU461342B2 (fr)
AU471461B2 (fr)
AU477824B2 (fr)
AU476873B1 (fr)
AR201432A1 (fr)
AR210729A1 (fr)
AU447540B2 (fr)
AU1891376A (fr)

Legal Events

Date Code Title Description
ST Notification of lapse